Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2020

View Archived Issues

How running away from your problems works

Blood studies identify new trait-related variants

Teaching T cells restraint

Biomica presents positive preclinical data for immune-oncology candidate BMC-128

4,6- and 5,7-disubstituted isoquinolines inhibiting PKCz show promise for rheumatoid arthritis

sEH inhibition decreases expression of proinflammatory cytokines and increases Tregs in a RA model

CLR-131 shows clinically meaningful ORR in refractory multiple myeloma in phase II CLOVER-1 study

ProTrans-2 study meets primary endpoint

GlaxoSmithKline begins healthy volunteer study with GSK-3882347 for urinary tract infections

Positive data for Ampion as potential treatment of patients with COVID-19

L-606, inhaled liposomal treprostinil-extended release in healthy volunteers

Topline data presented from study 402 of lumateperone in patients with bipolar depression

Bayer initiates enrollment in phase II CONCORD study of runcaciguat

Daiichi Sankyo describes new cytochrome P450 CYP26A1 inhibitors

New RET inhibitors identified at Sichuan Kelun-Biotech Biopharmaceutical

1st Bio Therapeutics patents ABL1/LRRK2 inhibitors

Insilico Medicine identifies new TNIK/MAP4K4 inhibitors

Hanmi Science synthesizes new EZH1/2 inhibitors

OX40 and OX40L as biomarkers for monitoring disease progression in chronic hepatitis B

Beijing Konruns begins phase I study of KC-1036 in advanced solid tumors

Cyclo Therapeutics reports further data from phase I/II study of Trappsol Cyclo in NPC1

elF4EBP3 as novel metastasis and survival biomarker in gastric cancer

Merck Sharp & Dohme opens phase I/II study of COVID-19 vaccine candidate V-591

Laekna and CMAB enter collaboration agreement to advance anti-PD-L1 antibody LAE-005

Sinovac reports phase I/II data on use of CoronaVac vaccine in elderly volunteers

Gannex and Galmed collaborate to study combination of ASC-41 and aramchol for NASH

S1PR2 identified as therapeutic target in nonalcoholic fatty liver disease

Ultra-sensitive antigen testing could help identify patients at risk for severe COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.